Cardioxyl Pharmaceuticals Receives $28,050,000 Series B Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8364ce60-4542-4c92-a170-abf82c40b108
Date
11/7/2012
Company Name
Cardioxyl Pharmaceuticals
Mailing Address
Exchange East 1450 Raleigh Road Chapel Hill, NC 27517 USA
Company Description
Cardioxyl Pharmaceuticals’ mission is the discovery and development of newclasses of safe and effective therapeutic agents for the treatment ofcardiovascular disease. Cardioxyl’s initial program is a novel medication forthe treatment of acute decompensated heart failure.
Website
http://www.cardioxyl.com
Transaction Type
Venture Equity
Transaction Amount
$28,050,000
Transaction Round
Series B
Proceeds Purposes
Proceeds from this latest round will be used to further advance Cardioxyl’s second-generation nitroxyl (HNO) donor programs for the treatment of acute and chronic heart failure.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor